[Clinical study on advanced non-Hodgkin's lymphoma with special reference to the results of chemotherapies with ACOP, ACOP-E and AclBEP regimen].
S
S
Nakamura
T
T
Yoshida
S
S
Ohtake
K
K
Itoh
K
K
Kobayashi
M
M
Kanno
J
J
Hirai
K
K
Tachimori
T
T
Matsuda
Y
Y
Saito
D015250:Aclarubicin; D000328:Adult; D000367:Age Factors; D000368:Aged; D000369:Aged, 80 and over; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use*; D003520:Cyclophosphamide / Q000008:administration & dosage; D003561:Cytarabine / Q000008:administration & dosage / Q000031:analogs & derivatives; D004317:Doxorubicin / Q000008:administration & dosage; D004334:Drug Administration Schedule; D005047:Etoposide / Q000008:administration & dosage; D005260:Female; D006801:Humans; D008228:Lymphoma, Non-Hodgkin / Q000188:drug therapy* / Q000401:mortality; D008297:Male; D008875:Middle Aged; D009279:Naphthacenes / Q000008:administration & dosage; D011239:Prednisolone / Q000008:administration & dosage; D012737:Sex Factors; D014750:Vincristine / Q000008:administration & dosage
D009279:Naphthacenes; D003561:Cytarabine; D014750:Vincristine; D005047:Etoposide; D015250:Aclarubicin; D004317:Doxorubicin; D003520:Cyclophosphamide; D011239:Prednisolone